When It Happens Panel Get involved: send your photos, videos, news & views by texting 'OXFORD NEWS' to 80360 or email
Oxford Biomedica hopes eye treatment problems over
5:30pm Thursday 5th September 2013 in News
GENE therapy company Oxford Biomedica is hoping for the all-clear after impurities were discovered in its potential treatment for eye disease.
In June the company announced it had voluntarily halted trials of four different eye treatments as a precautionary measure, because of “potential impurities derived from a widely-used third party raw material”.
Chief executive John Dawson told investors: “We’re confident our products are safe and our main priority is to be back treating patients as soon as possible.”
He said Biomedica and its commercial partner, drug giant Sanofi, would be presenting a dossier to European and US drug regulators with a view to working closely with them to resume trials as soon as possible.
Biomedica’s results for the first half of 2013 showed pre-tax losses increased to £6.7m from £5.7m.
The company employs 80 people at Oxford Science Park and in its Cowley factory.
Comments are closed on this article.